|
|
Volumn 8, Issue 5, 2003, Pages 188-189
|
|
Gleevec: Tailoring to fit
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE;
6 (2,6 DICHLOROPHENYL) 2 [3 (HYDROXYMETHYL)ANILINO] 8 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE;
ANTINEOPLASTIC AGENT;
IMATINIB;
PHOSPHOTRANSFERASE INHIBITOR;
PROTEIN TYROSINE KINASE INHIBITOR;
UNCLASSIFIED DRUG;
ACQUIRED IMMUNE DEFICIENCY SYNDROME;
ADVANCED CANCER;
BLAST CELL;
CANCER GROWTH;
CANCER MORTALITY;
CANCER RECURRENCE;
CANCER REGRESSION;
CANCER SURVIVAL;
CELL MUTANT;
CHRONIC MYELOID LEUKEMIA;
CLINICAL TRIAL;
CLONOGENESIS;
DRUG ACTIVITY;
DRUG APPROVAL;
DRUG CYTOTOXICITY;
DRUG DEVELOPMENT;
DRUG INHIBITION;
DRUG RESEARCH;
DRUG SAFETY;
DRUG SOLUBILITY;
DRUG TOLERABILITY;
EARLY DIAGNOSIS;
FOOD AND DRUG ADMINISTRATION;
GENE MUTATION;
GENETIC DISORDER;
HUMAN;
LYMPHOCYTE PROLIFERATION;
SHORT SURVEY;
SIDE EFFECT;
ANTINEOPLASTIC AGENTS;
ENZYME INHIBITORS;
HUMANS;
LEUKEMIA, MYELOID, CHRONIC;
PIPERAZINES;
PYRIDONES;
PYRIMIDINES;
|
|
EID: 0037336773
PISSN: 13596446
EISSN: None
Source Type: Journal
DOI: 10.1016/S1359-6446(03)02615-1 Document Type: Short Survey |
|
Times cited : (6)
|
|
References (2)
|
